Is BridgeBio Pharma (BBIO) Still Priced Fairly After Its 166% Share Price Surge?

Simply Wall St.01-11

If you are wondering whether BridgeBio Pharma's share price still reflects its underlying value after a strong run, you are not alone. The stock recently closed at US$77.25, with returns of 6.3% over ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602534536?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-11 07:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602534536","market":"sg","top_or_hot":-1,"title":"Is BridgeBio Pharma (BBIO) Still Priced Fairly After Its 166% Share Price Surge?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether BridgeBio Pharma's share price still reflects its underlying value after a strong run, you are not alone. The stock recently closed at US$77.25, with returns of 6.3% over ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-bridgebio-pharma-bbio-still-priced-fairly-after-its-166-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is BridgeBio Pharma (BBIO) Still Priced Fairly After Its 166% Share Price Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs BridgeBio Pharma (BBIO) Still Priced Fairly After Its 166% Share Price Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-bridgebio-pharma-bbio-still-priced-fairly-after-its-166-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether BridgeBio Pharma's share price still reflects its underlying value after a strong run, you are not alone. The stock recently closed at US$77.25, with returns of 6.3% over ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-bridgebio-pharma-bbio-still-priced-fairly-after-its-166-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-bridgebio-pharma-bbio-still-priced-fairly-after-its-166-s","article_id":"2602534536","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-bridgebio-pharma-bbio-still-priced-fairly-after-its-166-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602534536","pubTimestamp":1768087642,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether BridgeBio Pharma's share price still reflects its underlying value after a strong run, you are not alone.\nThe stock recently closed at US$77.25, with returns of 6.3% over the last 30 days, a 1.3% decline over the past week, and about 166% over the past year, while the 3 year return figure is very large.\nRecent news around BridgeBio Pharma has focused on its clinical stage pipeline, partnership activity and regulatory milestones. These factors can all influence...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BBIO":"BridgeBio Pharma, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"BridgeBio Pharma(BBIO)股价飙升166%后定价是否仍然公平？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"BBIO":1.5},"content_text":"If you are wondering whether BridgeBio Pharma's share price still reflects its underlying value after a strong run, you are not alone. The stock recently closed at US$77.25, with returns of 6.3% over the last 30 days, a 1.3% decline over the past week, and about 166% over the past year, while the 3 year return figure is very large. Recent news around BridgeBio Pharma has focused on its clinical stage pipeline, partnership activity and regulatory milestones. These factors can all influence how investors think about future cash flows and risk, and they help frame why the share price has moved so sharply over the past year and why expectations around the business are in the spotlight. Right now, BridgeBio Pharma has a valuation score of 2 out of 6. Next we will look at what different valuation methods say about that score, before finishing with a more holistic way to think about the stock's value.  BridgeBio Pharma scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: BridgeBio Pharma Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today using a required rate of return. For BridgeBio Pharma, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $597.3 million. Analysts provide explicit free cash flow forecasts out to 2030, with the projection for that year at about $1.9 billion, and Simply Wall St extrapolates further years from those inputs. Across the 2026 to 2035 period, the ten year free cash flow projections range from a loss of $178.9 million in 2026 to around $3.3 billion in 2035, all in dollars. These projected amounts are discounted back to today to arrive at an estimated intrinsic value per share of about $275.16. Compared with the recent share price of US$77.25, the DCF output suggests the stock is about 71.9% below this intrinsic value, which points to a materially undervalued share price on this model alone. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests BridgeBio Pharma is undervalued by 71.9%. Track this in your watchlist or portfolio, or discover 876 more undervalued stocks based on cash flows. BBIO Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for BridgeBio Pharma. Approach 2: BridgeBio Pharma Price vs Sales For companies where earnings are not yet positive or are highly variable, P/S is often a useful yardstick because it focuses on revenue rather than profit. It lets you compare what investors are paying for each dollar of sales, which can be helpful for clinical stage biotechs. What counts as a \"normal\" or \"fair\" P/S ratio usually reflects how investors view a company’s growth prospects and risk profile. Higher expected growth and lower perceived risk can support a higher multiple, while slower growth or higher uncertainty tends to point to a lower one. BridgeBio Pharma is currently trading on a P/S of 42.08x. That stands well above the Biotechs industry average of 12.39x and also above the peer group average of 17.71x. Simply Wall St’s Fair Ratio for BridgeBio Pharma is 26.36x, which is its proprietary view of what the P/S could be based on factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because the Fair Ratio incorporates these business characteristics rather than relying only on simple peer or industry comparisons, it can give you a more tailored reference point. Compared with the 26.36x Fair Ratio, the current 42.08x P/S suggests the shares are trading on a richer multiple than this framework would imply. Result: OVERVALUED NasdaqGS:BBIO P/S Ratio as at Jan 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1441 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your BridgeBio Pharma Narrative Earlier we mentioned that there is an even better way to think about valuation. Simply Wall St uses Narratives, where you tell a clear story about BridgeBio Pharma, link that story to specific forecasts for revenue, earnings and margins, and then see an implied fair value that you can compare with today’s price. All of this is available within an easy tool on the Community page that updates when new news or earnings arrive. One investor might plug in the higher end fair value estimate of about US$84.65 per share and side more with the US$95 analyst target, while another might lean closer to the lower US$41 target. The platform lets you see these different viewpoints side by side and decide how your own Narrative lines up before you choose whether the current price looks attractive or not. Do you think there's more to the story for BridgeBio Pharma? Head over to our Community to see what others are saying! NasdaqGS:BBIO 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BridgeBio Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602534536","isCrawlerRequest":true}